{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+600&page=17", "query": { "intervention": "Combination 600", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 472, "total_pages": 48, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+600&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+600&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T12:32:50.013Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01794520", "title": "Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2012-10-10", "completion_date": "2021-11-29", "has_results": true, "last_update_posted_date": "2023-04-10", "last_synced_at": "2026-10-31T12:32:50.013Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01794520" }, { "nct_id": "NCT00941499", "title": "Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "HAI Oxaliplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 140, "start_date": "2009-07", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-10-31T12:32:50.013Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00941499" }, { "nct_id": "NCT01046864", "title": "Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastro-Intestinal Cancer" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Brivanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "20 Years to 75 Years" }, "enrollment_count": 49, "start_date": "2010-02", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-09-16", "last_synced_at": "2026-10-31T12:32:50.013Z", "location_count": 3, "location_summary": "Los Angeles, California • Dallas, Texas • Temple, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Dallas", "state": "Texas" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01046864" }, { "nct_id": "NCT00004127", "title": "Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-02", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-10-31T12:32:50.013Z", "location_count": 21, "location_summary": "New Haven, Connecticut • Chicago, Illinois • Decatur, Illinois + 16 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004127" }, { "nct_id": "NCT01624246", "title": "Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Augmented Renal Clearance (ARC)", "Systemic Inflammatory Response Syndrome (SIRS)" ], "interventions": [ { "name": "Ceftaroline fosamil/Avibactam (CXL)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2012-05", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2017-04-07", "last_synced_at": "2026-10-31T12:32:50.013Z", "location_count": 19, "location_summary": "Fresno, California • Los Angeles, California • San Diego, California + 16 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01624246" }, { "nct_id": "NCT01466790", "title": "A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "PSI-7977 (GS7977)", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 168, "start_date": "2012-01", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-02-09", "last_synced_at": "2026-10-31T12:32:50.013Z", "location_count": 22, "location_summary": "Hoover, Alabama • Bakersfield, California • La Jolla, California + 19 more", "locations": [ { "city": "Hoover", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01466790" }, { "nct_id": "NCT02632448", "title": "A Study of LY2880070 in Participants With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Colorectal Cancer", "Breast Cancer", "Ovarian Cancer", "Colon Cancer", "Rectal Cancer", "Neoplasms", "Endometrial Cancer", "Soft Tissue Sarcoma", "Triple Negative Breast Cancer", "Pancreas Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "LY2880070", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Esperas Pharma Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2016-05-16", "completion_date": "2025-04-14", "has_results": false, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-10-31T12:32:50.013Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Detroit, Michigan", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632448" }, { "nct_id": "NCT05759949", "title": "First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "PIK3CA Mutation", "Solid Tumor, Adult", "HER2-negative Breast Cancer", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "Unresectable Solid Tumor", "Hormone Receptor Positive Tumor" ], "interventions": [ { "name": "RLY-5836", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Relay Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2023-03-29", "completion_date": "2025-04-11", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-31T12:32:50.013Z", "location_count": 7, "location_summary": "Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05759949" }, { "nct_id": "NCT06613685", "title": "Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "lepetegravir", "type": "DRUG" }, { "name": "lenacapavir pacfosacil", "type": "DRUG" }, { "name": "Bictegravir/emtricitabine/tenofovir alafenamide", "type": "DRUG" }, { "name": "lepetegravir/lenacapavir pacfosacil FDC", "type": "DRUG" }, { "name": "Placebo to Match BVY", "type": "DRUG" }, { "name": "Placebo to Match GS1720/GS-4182 FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2024-10-21", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-31T12:32:50.013Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Torrance", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06613685" }, { "nct_id": "NCT02498652", "title": "Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout" ], "interventions": [ { "name": "RDEA3170 2.5 mg", "type": "DRUG" }, { "name": "allopurinol 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ardea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 41, "start_date": "2015-07-28", "completion_date": "2016-06-02", "has_results": true, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-10-31T12:32:50.013Z", "location_count": 4, "location_summary": "Anaheim, California • DeLand, Florida • South Miami, Florida + 1 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "South Miami", "state": "Florida" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02498652" } ] }